&. $. , E. !. , !. E. Vq, and #. Tableaux, MEF-1 montre qu'à dose identique, l'eIPV provoque une plus forte réponse immunitaire chez la souris transgénique que le vaccin Sabin IPV de type 2 à la fois en termes de quantité d'anticorps et de protection contre la paralysie, cette dernière étant incomplète avec le Sabin- IPV après épreuve par une souche de Poliovirus sauvage de type 2 (Dragunsky, 2004.

J. W. Almond, G. Westrop, D. Evans, G. Dunn, P. D. Minor et al., Studies on the attenuation of the Sabin type 3 oral polio vaccine, Journal of Virological Methods, vol.17, issue.1-2, pp.183-192, 1987.
DOI : 10.1016/0166-0934(87)90081-4

J. Aunins, Viral vaccine production in cell culture. Dans Encyclopedia of cell technology, pp.1182-1217, 2003.

B. R. Aylward, R. Tangermann, R. Sutter, and S. L. Cochi, Polio Eradication, 2004.
DOI : 10.1086/498166

M. Baca-estrada and E. Griffiths, Regulation and standardization of IPV and IPV combination vaccines, Biologicals, vol.34, issue.2, pp.159-61, 2006.
DOI : 10.1016/j.biologicals.2006.03.001

W. A. Bakker, Y. E. Thomassen, A. G. Van-'t-oever, J. Westdjik, M. G. Van-oijen et al., Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV, Vaccine, vol.29, issue.41, pp.7188-96, 2011.
DOI : 10.1016/j.vaccine.2011.05.079

B. Blondel, T. Coudrec, N. Pavio, and F. Colbère-grapin, Biologie mol??culaire du poliovirus, Annales de l'Institut Pasteur / Actualit??s, vol.6, issue.2, pp.86-89, 1995.
DOI : 10.1016/0924-4204(96)83612-2

B. Blondel, A. Autret, S. Martin-latil, L. Mousson, I. Pelletier et al., Poliovirus et apoptose, Virologie, vol.10, pp.7-20, 2006.
URL : https://hal.archives-ouvertes.fr/pasteur-00167563

S. Blume and I. Geesink, ESSAY ON SCIENCE AND SOCIETY:A Brief History of Polio Vaccines, Science, vol.288, issue.5471, pp.1593-94, 2000.
DOI : 10.1126/science.288.5471.1593

B. Blüml and G. , Microcarrier cell culture technology. Dans Methods in Biotechnology - Animal cell biotechnology Methods and protocols Second Edition, 2007.

M. Bonnet and A. Dutta, World wide experience with inactivated poliovirus vaccine, Vaccine, vol.26, issue.39, pp.4978-83, 2008.
DOI : 10.1016/j.vaccine.2008.07.026

S. Bourhrara, Vers une éradication de la poliomyélite, Thèse de doctorat en pharmacie, 2009.

J. Cello, A. V. Paul, and E. Wimmer, Chemical Synthesis of Poliovirus cDNA: Generation of Infectious Virus in the Absence of Natural Template, Science, vol.297, issue.5583, pp.1016-1034, 2002.
DOI : 10.1126/science.1072266

T. Chen and K. Chen, Investigation and application progress of Vero Cell Serum-free Culture. Intern, J. Biol, vol.1, pp.41-47, 2009.

C. Chezzi, C. J. Dommann, N. Blackburn, E. Maselesele, J. Mcanerney et al., Genetic stability of oral polio vaccine prepared on primary monkey kidney cells or Vero cells ??? effects of passage in cell culture and the human gastrointestinal tract, Vaccine, vol.16, issue.20, pp.2031-2069, 1998.
DOI : 10.1016/S0264-410X(98)00079-6

C. W. Cockburn, The work of the WHO consultative group on poliomyelitis vaccines, Bull. World Health Org, vol.66, pp.143-54, 1988.

D. Jesus and N. H. , Epidemics to eradication: the modern history of poliomyelitis, Virology Journal, vol.4, issue.1, 2007.
DOI : 10.1186/1743-422X-4-70

E. M. Dragunsky, A. P. Ivanov, V. R. Wells, A. V. Ivshina, G. V. Rezapkin et al., Evaluation of Immunogenicity and Protective Properties of Inactivated Poliovirus Vaccines: A New Surrogate Method for Predicting Vaccine Efficacy, The Journal of Infectious Diseases, vol.190, issue.8, 2004.
DOI : 10.1086/424524

M. Duchêne, Production, testing and perspectives of IPV and IPV combination vaccines: GSK biologicals' view, Biologicals, vol.34, issue.2, pp.163-66, 2006.
DOI : 10.1016/j.biologicals.2006.03.010

G. Dunn and K. M. Chumakov, Mutant analysis by PCR and restriction enzyme cleavage (MAPREC) for Oral Poliovirus (Sabin) Vaccine Types 1, 2 or 3. World Heath Organization, pp.1-29, 2011.

L. H. Falleiros-carvalho and L. Y. Weckx, Universal use of inactivated polio vaccine, 2006.

M. Ferguson, D. J. Wood, and P. D. Minor, Antigenic structure of poliovirus in inactivated vaccines, Journal of General Virology, vol.74, issue.4, pp.685-90, 1993.
DOI : 10.1099/0022-1317-74-4-685

J. Furesz, Developments in the production and quality control of poliovirus vaccines ??? Historical perspectives, Biologicals, vol.34, issue.2, pp.87-90, 2006.
DOI : 10.1016/j.biologicals.2006.02.008

H. Graf, Manufacturing and supply of monovalent oral polio vaccines, Biologicals, vol.34, issue.2, pp.141-185, 2006.
DOI : 10.1016/j.biologicals.2006.03.011

E. Heinsbroek and J. Ruitenberg, The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox, Vaccine, vol.28, issue.22, pp.3778-83, 2010.
DOI : 10.1016/j.vaccine.2010.02.095

F. Horaud, Albert B. Sabin and the Development of Oral Poliovaccine, Biologicals, vol.21, issue.4, pp.311-327, 1993.
DOI : 10.1006/biol.1993.1089

D. M. Horstmann, THE POLIOMYELITIS STORY, The Pediatric Infectious Disease Journal, vol.5, issue.3, pp.79-80, 1985.
DOI : 10.1097/00006454-198605000-00042

R. L. Huckstep, Poliomyelitis: A guide for developing countries, including appliances and rehabilitation for the disabled, 1975.

V. Institut-de and . Sanitaire, Conduite à tenir devant un cas de polio suspecté ou confirmé ou devant un isolement de Poliovirus, Bull. Epidemiol. Hebd, vol.4647, pp.203-208, 2000.

G. Kersten, T. Hazendonk, and C. Beuvery, Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains, Vaccine, vol.17, issue.15-16, pp.2059-66, 1999.
DOI : 10.1016/S0264-410X(98)00409-5

H. Kreeftenberg, T. Van-der-velden, G. Kersten, N. Van-der-heuvel, and M. De-bruijn, Technology transfer of Sabin-IPV to new developing country markets, Biologicals, vol.34, issue.2, pp.155-58, 2006.
DOI : 10.1016/j.biologicals.2006.02.011

Z. Lu, M. Douthitt, and M. Taffs, Quantitative aspects of the mutant analysis by PCR and restriction enzyme cleavage (MAPREC)., Genome Research, vol.3, issue.3, pp.176-80, 1993.
DOI : 10.1101/gr.3.3.176

A. J. Macadam, S. R. Pollard, G. Ferguson, G. Dunn, R. Skuce et al., The 5??? noncoding region of the type 2 poliovirus vaccine strain contains determinants of attenuation and temperature sensitivity, Virology, vol.181, issue.2, pp.451-459, 1991.
DOI : 10.1016/0042-6822(91)90877-E

M. Bean, M. A. Thoms, M. Albrecht, P. Cuthie, and J. C. , Serologic response to oral poliovaccine and enhanced-potency inactivated poliovaccine, Am. J. Epidemiol, vol.128, pp.615-643, 1988.

J. L. Melnick, Virus inactivation: lessons from the past, Dev. Biol. Stand, vol.75, pp.26-36, 1991.

O. Merten, R. Wu, E. Couvé, and R. Crainic, Evaluation of the serum-free medium MDSS2 for the production of Poliovirus on Vero cells in bioreactors, Cytotechnology, vol.25, issue.1/3, pp.35-44, 1997.
DOI : 10.1023/A:1007999313566

P. D. Minor, The molecular biology of poliovaccines, Journal of General Virology, vol.73, issue.12, pp.3065-77, 1992.
DOI : 10.1099/0022-1317-73-12-3065

P. D. Minor, Gaps in scientific knowledge for the post eradication world, Biologicals, vol.34, issue.2, pp.167-70, 2006.
DOI : 10.1016/j.biologicals.2006.02.006

B. Montagnon, J. Vincent-falquet, and B. Fanget, Thousand litre scale microcarrier culture of Vero cells for killed polio virus vaccine. Promising results, Dev. Biol. Stand, vol.55, pp.37-42, 1983.

B. J. Montagnon, B. Fanget, and J. C. Vincent-falquet, Industrial-Scale Production of Inactivated Poliovirus Vaccine Prepared by Culture of Vero Cells on Microcarrier, Clinical Infectious Diseases, vol.6, issue.Supplement_2, pp.341-345, 1984.
DOI : 10.1093/clinids/6.Supplement_2.S341

B. J. Montagnon and B. J. Fanget, Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine, p.349, 1985.

S. Mueller, E. Wimmer, and J. Cello, Poliovirus and poliomyelitis: A tale of guts, brains, and an accidental event, Virus Research, vol.111, issue.2, pp.175-93, 2005.
DOI : 10.1016/j.virusres.2005.04.008

A. D. Murdin, L. Barreto, and S. Plotkin, Inactivated poliovirus vaccine: past and present experience, Vaccine, vol.14, issue.8, pp.735-781, 1996.
DOI : 10.1016/0264-410X(95)00211-I

N. Nathanson, David Bodian's Contribution to the Development of Poliovirus Vaccine, American Journal of Epidemiology, vol.161, issue.3, 2005.
DOI : 10.1093/aje/kwi033

N. Nathanson, The pathogenesis of poliomyelitis: what we don't know, Adv. Virus Res, vol.71, pp.1-50, 2008.

J. Newman, S. Tirell, C. Ullman, P. Piatti, and F. Brown, Stabilising oral poliovaccine at high ambient temperatures, Vaccine, vol.13, issue.15, pp.1431-1466, 1995.
DOI : 10.1016/0264-410X(95)00070-H

A. Nomoto, Molecular aspects of poliovirus pathogenesis, Proceedings of the Japan Academy, Series B, vol.83, issue.8, pp.266-75, 2007.
DOI : 10.2183/pjab.83.266

S. M. Oberste, D. Moore, B. Anderon, M. A. Pallansch, D. C. Pevear et al., In Vitro Antiviral Activity of V-073 against Polioviruses, Vitro Antiviral Activity of V-073 against Polioviruses, pp.4501-4504, 2009.
DOI : 10.1128/AAC.00671-09

P. Ogra, D. Karzon, F. Rightland, and M. Macgillivray, Immunoglobulin Response in Serum and Secretions after Immunization with Live and Inactivated Poliovaccine and Natural Infection, New England Journal of Medicine, vol.279, issue.17, pp.893-900, 1968.
DOI : 10.1056/NEJM196810242791701

I. M. Onorato, J. F. Modlin, A. Mc-bean-marshall, M. Thoms, G. Lovonsky et al., Mucosal Immunity Induced by Enhanced-Potency Inactivated and Oral Polio Vaccines, Journal of Infectious Diseases, vol.163, issue.1, pp.1-6, 1991.
DOI : 10.1093/infdis/163.1.1

O. Mondiale-de-la-santé, Initiative Mondiale pour l'Eradication de la Poliomyélite-Plan Stratégique, 2010.

P. Patriarca, P. Wright, and T. John, Factors Affecting the Immunogenicity of Oral Poliovirus Vaccine in Developing Countries: Review, Clinical Infectious Diseases, vol.13, issue.5, pp.926-965, 1991.
DOI : 10.1093/clinids/13.5.926

S. A. Plotkin and E. Vidor, Poliovirus vaccine-inactivated. Dans Vaccines (5th édition), pp.605-629, 2008.

V. Prikazsky, R. G. Leroux-roels, P. Van-damme, A. Safary, B. Colaud et al., Comparative pre-clinical and clinical experience with oral polio vaccine produced on MRC-5 cells or on primary monkey kidney cells, Vaccine, vol.23, issue.33, pp.4219-4246, 2005.
DOI : 10.1016/j.vaccine.2005.04.002

V. R. Racaniello, One hundred years of poliovirus pathogenesis, Virology, vol.344, issue.1, pp.9-16, 2006.
DOI : 10.1016/j.virol.2005.09.015

M. Rey and M. P. Girard, The global eradication of poliomyelitis: Progress and problems, Comparative Immunology, Microbiology and Infectious Diseases, vol.31, issue.2-3, pp.317-342, 2008.
DOI : 10.1016/j.cimid.2007.07.013

G. Rezapkin, J. Martin, and K. Chumakov, Analysis of antigenic profiles of inactivated poliovirus vaccine and vaccine-derived polioviruses by block-ELISA method, Biologicals, vol.33, issue.1, pp.29-39, 2005.
DOI : 10.1016/j.biologicals.2004.11.001

S. Robertson, Les bases immunologiques de la vaccination-la poliomyélite WHO, pp.93-109, 1993.

A. Sabin and L. Boulger, History of Sabin attenuated poliovirus oral live vaccine strains, Journal of Biological Standardization, vol.1, issue.2, pp.115-123, 1973.
DOI : 10.1016/0092-1157(73)90048-6

S. Salmon, Le syndrome post polio: demandes exprimées par les patients et mises en place d'une filière spécifique en Lorraine, Thèse de doctorat en médecine, 2008.

K. Shah, SV40 and human cancer: A review of recent data, International Journal of Cancer, vol.19, issue.2, pp.215-238, 2007.
DOI : 10.1093/jnci/djg074

T. Skern, 100 years polioivirus: from discovery to eradication. A meeting report, Arch. Virol, vol.5, pp.1371-81, 2010.

R. W. Sutter, O. M. Knew, and S. L. Cochi, Poliovirus vaccine-live, pp.631-685, 2008.

A. L. Van-wezel, Growth of Cell-strains and Primary Cells on Micro-carriers in Homogeneous Culture, Nature, vol.130, issue.5110, pp.64-65, 1967.
DOI : 10.1002/bit.260060403

V. Gouandjika and I. , Circulation et dérive génétique du polioivirus en Afrique Centrale et de l'Ouest. Thèse de doctorat de l, 2006.

R. Wahid, M. J. Cannon, and M. &chow, Virus-specific CD4+ and CD8+ cytotoxic Tcell responses and long-term T-cell memory in individuals vaccinated against polio, 2005.

J. Westdjik, D. Brugmans, J. Martin, A. Van-'t-oever, W. A. Bakker et al., Characterization and standardization of Sabin based inactivated polio vaccine: Proposal for a new antigen unit for inactivated polio vaccines, Vaccine, vol.29, issue.18, pp.3390-97, 2011.
DOI : 10.1016/j.vaccine.2011.02.085

D. Wood and A. Heath, A WHO Collaborative Study of Immunogenicity Assays of Inactivated Poliovirus Vaccines, Biologicals, vol.23, issue.4, pp.301-312, 1995.
DOI : 10.1006/biol.1995.0049

D. Wood and A. Heath, A WHO collaborative study on assays of the antigenic content of inactivated poliovirus vaccines, Biologicals, vol.23, issue.1, pp.83-94, 1995.
DOI : 10.1016/1045-1056(95)90017-9

D. Wood, A. Heath, G. Kersten, T. Hazendonk, M. Lantinga et al., A New WHO International Reference Reagent for Use in Potency Assays of Inactivated Poliomyelitis Vaccine, Biologicals, vol.25, issue.1, pp.59-64, 1997.
DOI : 10.1006/biol.1996.0060

A. Wringe, P. E. Fine, R. W. Sutter, and O. M. Kew, Estimating the Extent of Vaccine-Derived Poliovirus Infection, PLoS ONE, vol.50, issue.(Pt 5), pp.1-11, 2008.
DOI : 10.1371/journal.pone.0003433.t002

O. Wyman, Global Post-eradication IPV Supply and Demand Assessment: Integrated Findings. Assessement commissioned by the Bill & Melinda Gates Foundation. The PolioPipeline, 2009.

H. Zeichhardt and H. Grunert, Chapitre 213 : Enteroviruses: Polioviruses, Coxsackie viruses, Echoviruses and Enteroviruses 68-71, 2004.